Current status of HLA haplo-identical transplantation using post-transplantation cyclophosphamide

Abstract

 Outcomes of HLA haplo-identical transplantation using post-transplantation cyclophosphamide (PT/Cy-haplo) are similar to those of HLA-matched related/unrelated transplantation. Unlike classical HLA haplo-identical transplantation, PT/Cy-haplo does not require expensive T-cell depletion. Furthermore, accumulating evidences, including meta-analysis data, have indicated that PT/Cy-haplo may have a significant advantage over HLA-matched transplantation, concerning the low incidence of clinically significant, moderate-to-severe chronic graft-versus-host disease. This clinical advantage of PT/Cy-haplo could contribute to economic medical benefits by reducing the cost and improve the quality of life of the patients. The establishment of PT/Cy-haplo could necessitate the recalibration of the donor selection algorithm.